Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.81 Million USD | 68.31% |
| 2022 | -12.03 Million USD | 63.48% |
| 2021 | -32.96 Million USD | -104.29% |
| 2020 | -16.13 Million USD | -218.72% |
| 2019 | -5.06 Million USD | 33.25% |
| 2018 | -7.58 Million USD | 7.6% |
| 2017 | -8.2 Million USD | -67.71% |
| 2016 | -4.89 Million USD | 77.79% |
| 2015 | -22.03 Million USD | 56.21% |
| 2014 | -50.32 Million USD | -91.26% |
| 2013 | -26.3 Million USD | -48.79% |
| 2012 | -17.68 Million USD | -55.62% |
| 2011 | -11.36 Million USD | -876.93% |
| 2010 | 1.46 Million USD | 633.16% |
| 2009 | 199.47 Thousand USD | 248.62% |
| 2008 | 57.21 Thousand USD | 210.87% |
| 2007 | 18.4 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | -9.82 Million USD | 18.43% |
| 2023 Q4 | -3.81 Million USD | 36.8% |
| 2023 Q3 | -6.03 Million USD | 7.21% |
| 2023 Q2 | -6.5 Million USD | 33.76% |
| 2023 FY | -3.81 Million USD | 68.31% |
| 2022 Q4 | -12.03 Million USD | 25.93% |
| 2022 FY | -12.03 Million USD | 63.48% |
| 2022 Q3 | -16.25 Million USD | 26.51% |
| 2022 Q2 | -22.11 Million USD | 20.97% |
| 2022 Q1 | -27.98 Million USD | 15.11% |
| 2021 Q4 | -32.96 Million USD | -104.51% |
| 2021 FY | -32.96 Million USD | -104.29% |
| 2021 Q1 | -14.66 Million USD | 9.14% |
| 2021 Q2 | -19.47 Million USD | -32.85% |
| 2021 Q3 | -16.12 Million USD | 17.24% |
| 2020 Q2 | -3.49 Million USD | -247.12% |
| 2020 Q1 | -1 Million USD | 80.09% |
| 2020 Q3 | -8.08 Million USD | -131.04% |
| 2020 Q4 | -16.13 Million USD | -99.62% |
| 2020 FY | -16.13 Million USD | -218.72% |
| 2019 FY | -5.06 Million USD | 33.25% |
| 2019 Q3 | -6.51 Million USD | 41.8% |
| 2019 Q2 | -11.19 Million USD | -218.72% |
| 2019 Q1 | -3.51 Million USD | 50.17% |
| 2019 Q4 | -5.06 Million USD | 22.28% |
| 2018 Q4 | -7.04 Million USD | 18.72% |
| 2018 Q1 | -7.51 Million USD | 8.42% |
| 2018 Q2 | -4.66 Million USD | 38.0% |
| 2018 Q3 | -8.67 Million USD | -86.06% |
| 2018 FY | -7.58 Million USD | 7.6% |
| 2017 Q2 | -4.94 Million USD | -118.95% |
| 2017 FY | -8.2 Million USD | -67.71% |
| 2017 Q4 | -8.2 Million USD | -354.26% |
| 2017 Q3 | -1.8 Million USD | 63.42% |
| 2017 Q1 | -2.25 Million USD | 53.9% |
| 2016 Q3 | -7.41 Million USD | -14.96% |
| 2016 Q2 | -6.45 Million USD | 41.95% |
| 2016 Q4 | -4.89 Million USD | 34.0% |
| 2016 FY | -4.89 Million USD | 77.79% |
| 2016 Q1 | -11.11 Million USD | 49.56% |
| 2015 Q2 | -36.78 Million USD | 14.99% |
| 2015 FY | -22.03 Million USD | 56.21% |
| 2015 Q1 | -43.27 Million USD | 14.01% |
| 2015 Q4 | -22.03 Million USD | 27.89% |
| 2015 Q3 | -30.55 Million USD | 16.92% |
| 2014 Q2 | -65.63 Million USD | 16.1% |
| 2014 Q3 | -56.83 Million USD | 13.41% |
| 2014 Q4 | -50.32 Million USD | 11.45% |
| 2014 FY | -50.32 Million USD | -91.26% |
| 2014 Q1 | -78.22 Million USD | -197.33% |
| 2013 Q3 | -32.07 Million USD | -157.45% |
| 2013 Q2 | -12.45 Million USD | 24.63% |
| 2013 Q1 | -16.52 Million USD | 6.53% |
| 2013 FY | -26.3 Million USD | -48.79% |
| 2013 Q4 | -26.3 Million USD | 17.96% |
| 2012 Q2 | -6.8 Million USD | 17.94% |
| 2012 Q4 | -17.68 Million USD | 12.75% |
| 2012 Q3 | -20.26 Million USD | -197.84% |
| 2012 Q1 | -8.29 Million USD | 27.02% |
| 2012 FY | -17.68 Million USD | -55.62% |
| 2011 Q4 | -11.36 Million USD | -62.46% |
| 2011 Q3 | -6.99 Million USD | 16.49% |
| 2011 Q2 | -8.37 Million USD | -83.71% |
| 2011 Q1 | -4.55 Million USD | -411.71% |
| 2011 FY | -11.36 Million USD | -876.93% |
| 2010 Q3 | 818.16 Thousand USD | 204.19% |
| 2010 FY | 1.46 Million USD | 633.16% |
| 2010 Q2 | 268.96 Thousand USD | 215.27% |
| 2010 Q1 | -233.34 Thousand USD | -216.98% |
| 2010 Q4 | 1.46 Million USD | 78.75% |
| 2009 Q4 | 199.47 Thousand USD | 185.5% |
| 2009 Q3 | 69.86 Thousand USD | 1.38% |
| 2009 Q2 | 68.91 Thousand USD | 1.9% |
| 2009 FY | 199.47 Thousand USD | 248.62% |
| 2009 Q1 | 67.63 Thousand USD | 18.2% |
| 2008 Q4 | 57.21 Thousand USD | 16.28% |
| 2008 Q2 | 45.29 Thousand USD | 33.71% |
| 2008 Q3 | 49.2 Thousand USD | 8.65% |
| 2008 FY | 57.21 Thousand USD | 210.87% |
| 2008 Q1 | 33.87 Thousand USD | 84.03% |
| 2007 Q4 | 18.4 Thousand USD | 72.62% |
| 2007 Q3 | 10.66 Thousand USD | 0.0% |
| 2007 FY | 18.4 Thousand USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 22.836% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 103.57% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 94.884% |
| Azitra, Inc. | -910.04 Thousand USD | -319.211% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 9.981% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 425.43% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 173.549% |
| CEL-SCI Corporation | 9.42 Million USD | 140.473% |
| iBio, Inc. | -9.75 Million USD | 60.872% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 88.258% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 46.649% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -197.814% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 970.123% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -878.205% |
| NanoViricides, Inc. | -4.79 Million USD | 20.484% |
| Oragenics, Inc. | -3.17 Million USD | -20.317% |
| BiomX Inc. | -772 Thousand USD | -394.171% |
| BiomX Inc. | -772 Thousand USD | -394.171% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 244.125% |
| Palatin Technologies, Inc. | -8.93 Million USD | 57.313% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 127.531% |